Author's Profile

Rosie Bradbury

Senior Venture Capital Reporter

Rosie Bradbury was a senior reporter covering startups and venture capital for PitchBook News. Based in New York, she previously reported for the Bureau of Investigative Journalism, Business Insider and Wired. Rosie studied history and politics at the University of Cambridge.

rosie-headshot.jpg

Articles by Rosie Bradbury

3 charts to catch up on the OpenAI-Anthropic rivalry

For the first time, Anthropic is reportedly worth more than its chief rival, OpenAI.
May 15, 2026

Fervo rides data center energy boom with 35% IPO pop

The energy startup, which develops next-generation geothermal technology, raised $1.89 billion in its upsized IPO.
May 13, 2026

E-scooter rental company Lime files for IPO as debt maturities loom

The scooter rental industry has struggled for years, despite massive early VC support—Lime is a rare survivor
May 8, 2026

Meet VC firms’ new rising stars

They have stellar resumes, diverse backgrounds and can-do attitudes.
May 8, 2026

A big question for brain-computer interface tech: How big is the market?

VCs are investing more in the technology in service of a grand vision of a digital, eternal life. But user acquisition is still a big hurdle.
May 7, 2026

SpaceX’s earliest investors face a wild card: Nasdaq’s new ‘fast entry’ rule

Funds like the highly popular QQQ that track the Nasdaq 100 will be compelled to buy a lot of SpaceX shares very quickly.
May 4, 2026

US ‘care deserts’ crisis may push regulators toward a more AI-friendly stance

There is a patchwork of state regulations for AI in healthcare—demand from patients and burned-out clinicians may spur broad adoption.
April 29, 2026

Eli Lilly hedges against GLP-1 revenue drop-off with $7B acquisition

The big pharma companies are using their cash to prepare for what comes after the GLP-1 boom and patent cliff.
April 20, 2026

OpenAI’s life sciences push energizes VCs

OpenAI has jumped into a category startup investors assumed it’d avoid. But they’re welcoming the move.
April 17, 2026

Biotech IPOs poised for a comeback—but only for some

A GLP-1 maker and a protein biomarker detection company are the latest to head for biotech IPOs. M&A activity is helping bolster that.
April 15, 2026